MRNA - Is There Room for Latecomers to the COVID-19 Party?
In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , talks with host Brian Orelli about how better-designed neutralizing antibodies can still make an impact in the crowded COVID-19 treatment and vaccine space. Mark Brunswick, senior vice president of regulatory affairs at Sorrento, also chimes in on the benefits of the company's antibody therapies. Sorrento is developing STI-1499 (COVI-Guard) as well as a second-generation antibody called STI-2020 (COVI-AMG).
Brian Orelli : So we have a vaccine from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) , which is showing about more than 90 percent effectiveness, and Moderna 's (NASDAQ: MRNA) on their heels with another vaccine, and we have quite a few other ones in phase 3 development. We have an antiviral from Gilead Sciences (NASDAQ: GILD) that's received emergency use authorization, and a therapeutic antibody from Eli Lilly (NYSE: LLY) that also has an authorization. Regeneron (NASDAQ: REGN) has an antibody cocktail that's under review by the FDA, and the data looks pretty promising. Then last time I checked, there was a 288 different COVID-19 tests that have been authorized by the FDA.
For further details see:
Is There Room for Latecomers to the COVID-19 Party?